Human platelet lysate (HPL) is derived from platelets collected from human blood. It is serum-free and xenogeneic-free substitute for fetal bovine serum that is commonly used in cell culture media. HPL contains a diverse and homologous mixture of growth factors which assist in proliferation and differentiation of cells in culture. It is extensively used in cell-based therapies, tissue engineering and regenerative medicine applications such as wound healing, musculoskeletal disorders, and cell & gene therapy.
The global Human Platelet Lysate Market is estimated to be valued at Us$ 61.06 Bn in 2024 and is expected to exhibit a CAGR Of 9.4% over the forecast period 2024 To 2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
Growing usage of HPL in regenerative medicine is expected to drive the market growth during the forecast period. HPL serves as an optimal growth supplement for mesenchymal stem cells and other primary cells, making it a promising alternative to fetal bovine serum. It stimulates secretion of growth factors and various cytokines from platelets which assist cell migration, proliferation, differentiation into tissues. Due to these benefits HPL is increasingly preferred over FBS in fabrication of skin grafts, bone grafts, cartilage grafts and other regenerative products. According to research, HPL derived mesenchymal stem/stromal cells may provide off-the-shelf therapeutic products for several clinical indications in future. Thus, expanding application of HPL in regenerative medicine field will present lucrative opportunities for growth of the human platelet lysate market during the forecast period.
Porter’s Analysis
Threat of new entrants: The human platelet lysate market requires high capital investment for research and production facilities limiting the threat of new entrants. Strict regulations by food and drug administration for new players also poses challenges.
Bargaining power of buyers: The presence of substitute products like fetal bovine serum limits the bargaining power of buyers. However, cost benefits of human platelet lysate over fetal bovine serum increases its demand.
Bargaining power of suppliers: Major companies controlling the supply of plasma results in higher bargaining power of suppliers. However, new fractionation facilities are increasing competition between suppliers.
Threat of new substitutes: Alternatives like animal serum are still used widely but regulations supporting use of human derived products can increase demand for human platelet lysate.
Competitive rivalry: Major global players dominate the market but regional small players are increasing competition.
SWOT Analysis
Strength: High biocompatibility and clinical efficacy of human platelet lysate for development of advanced therapies. Growing demand for human derived cell culture media.
Weakness: High production costs and regulatory complexities. Requirement of donations and expertise in extraction process.
Opportunity: Increasing investments in regenerative medicine provides scope for commercialization. rising prevalence of chronic diseases favor research activities.
Threats: Stringent regulations delay product approvals. Ethical issues involving human tissue can negatively impact market.
Key Takeaways
The Global Human Platelet Lysate Market Demand is expected to witness high growth during the forecast period of 2024 to 2031. The market size for 2024 is US$ 61.06 Bn registering a CAGR of 9.4% through 2031.
Regional analysis:
North America dominates currently due to large patient pool and advanced healthcare infrastructure. However, Asia Pacific will grow at fastest rate due to rising biologics industry and stem cell research in India, China, and Japan.
Key players:
Key players operating in the human platelet lysate market are Air Methods Corporation, Deccan Charters, Scandinavian Air Ambulance, Air Ambulance Specialists, Air Charter Service, Envision Healthcare Companies, Falck Danmark A/S, AMR Air Ambulance, AirMed International, Express Aviation Services, ALPHASTAR. Major players are investing in R&D to develop xeno-free cell culture products.
Get More Insights On This Topic :
https://www.ukwebwire.com/human-platelet-lysate-market-is-expected-to-be-flourished/
Comments
0 comment